Welcome to our dedicated page for Kyverna Therapeutics news (Ticker: KYTX), a resource for investors and traders seeking the latest updates and insights on Kyverna Therapeutics stock.
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a clinical-stage biopharmaceutical company focused on developing CD19-targeting CAR T-cell therapies for autoimmune diseases, and its news flow reflects this focus. Company updates frequently highlight progress with its lead autologous CAR T-cell therapy candidate, mivocabtagene autoleucel (miv-cel, KYV-101), in B-cell-driven autoimmune conditions.
Visitors to this KYTX news page can review announcements on Kyverna’s registrational trials in stiff person syndrome (SPS) and generalized myasthenia gravis (gMG). Recent press releases describe positive topline data from the KYSA-8 registrational Phase 2 trial in SPS and interim Phase 2 data from the KYSA-6 registrational Phase 2/3 trial in gMG, including reported effects on disability, mobility, and disease activity scores, as well as safety outcomes such as the absence of high-grade cytokine release syndrome or ICANS in the reported datasets.
News items also cover Kyverna’s broader development and financing activities. These include business updates and quarterly financial results, a loan facility with Oxford Finance LLC, and public equity offerings under an effective shelf registration statement on Form S-3. Additional releases describe investigator-initiated trials in multiple sclerosis and rheumatoid arthritis, Phase 1/2 trials in lupus nephritis, and the advancement of KYV-102, which the company characterizes as using a whole blood rapid manufacturing process.
Investors and followers of KYTX can use this page to track Kyverna’s press releases on clinical milestones, regulatory plans such as an anticipated BLA submission for SPS, corporate presentations at healthcare conferences, leadership and governance changes, and capital-raising transactions. Checking this feed provides a consolidated view of how the company reports its progress in autoimmune CAR T-cell therapy and related corporate developments.
Kyverna Therapeutics (NASDAQ: KYTX) provided a corporate update and 2026 priorities on Jan 12, 2026, highlighting late‑stage progress for its CAR T candidate miv‑cel. Key items: Kyverna plans to file a BLA for stiff person syndrome (SPS) in 1H 2026 after positive registrational topline data; the first patient has enrolled in the Phase 3 portion of the gMG KYSA‑6 trial; an IND for KYV‑102 was accepted by FDA in Jan 2026; a December 2025 follow‑on offering raised approximately $105M, and cash, cash equivalents, and marketable securities were ~$279M as of Dec 31, 2025, extending runway into 2028. Christi Shaw was appointed Executive Chairperson to strengthen CAR T commercialization experience.
Kyverna Therapeutics (Nasdaq: KYTX) announced that CEO Warner Biddle will present at the J.P. Morgan 2026 Healthcare Conference in San Francisco on January 14, 2026 at 9:45 a.m. PT.
Investors can access a live audio webcast via the company's Investors page at ir.kyvernatx.com. A replay will be available on the website for 30 days after the conference.
Kyverna Therapeutics (Nasdaq: KYTX) priced an underwritten public offering of 13,333,333 common shares at $7.50 per share to raise approximately $100 million gross, before underwriting discounts, commissions and offering expenses. The offering is expected to close on or about December 18, 2025, and Kyverna granted a 30-day option for underwriters to buy up to 1,999,999 additional shares at the public offering price less underwriting discounts and commissions.
J.P. Morgan, Leerink Partners, Morgan Stanley and Wells Fargo Securities are joint book-running managers. The securities are offered under an effective Form S-3 shelf registration declared effective on April 15, 2025.
Kyverna Therapeutics (Nasdaq: KYTX) announced a proposed underwritten public offering of $100,000,000 of common stock on December 15, 2025, with a 30-day underwriter option to purchase up to an additional $15,000,000 of shares at the public offering price, less underwriting discounts and commissions.
All shares will be sold by Kyverna and the offering is being led by J.P. Morgan, Leerink Partners, Morgan Stanley and Wells Fargo Securities. The offering is subject to market and other conditions and will be made pursuant to an effective Form S-3 shelf registration (File No. 333-286180); a preliminary prospectus supplement will be filed with the SEC.
Kyverna Therapeutics (Nasdaq: KYTX) announced positive topline results from the registrational Phase 2 KYSA-8 trial of miv-cel (KYV-101) in stiff person syndrome (SPS) on December 15, 2025. In 26 dosed patients at the Week 16 primary analysis, miv-cel achieved a median 46% improvement in timed 25-foot walk (T25FW) vs baseline (p=0.0002) and 81% of patients exceeded a clinically meaningful 20% T25FW improvement. All secondary endpoints showed highly significant benefits (all p<0.0001).
Safety was manageable with no high-grade CRS or ICANS; Grade 3/4 neutropenia was observed. Kyverna plans a BLA submission in 1H 2026 and will present full data at a 2026 medical conference.
Kyverna Therapeutics (Nasdaq: KYTX) will host a live webcast and conference call on Monday, December 15, 2025 at 8:00 AM ET to review topline results from the registrational Phase 2 KYSA-8 clinical trial evaluating KYV-101 in stiff person syndrome (SPS).
Registration is required to receive a dial-in number and unique PIN; the event can also be accessed via live webcast. Presentation materials will be posted in the Events & Presentations section of Kyverna's investor relations website and an archived replay will be available after the call.
Kyverna Therapeutics (Nasdaq: KYTX) reported Q3 2025 results and a business update, highlighting clinical progress and financing to support late‑stage programs.
Key points: topline SPS (KYSA-8) registrational data now expected in early 2026 with a BLA submission anticipated in 1H 2026; positive interim Phase 2 gMG (KYSA-6) data showing 100% (6/6) patients with mean MG‑ADL −8.0 and QMG −7.7 at 24 weeks and no high‑grade CRS or ICANS; IND for KYV‑102 on track for Q4 2025. Financially, cash and equivalents were $171.1M as of Sept 30, 2025, and Kyverna closed a loan facility up to $150M (initial $25M drawn), supporting a cash runway into 2027.
Kyverna Therapeutics (Nasdaq: KYTX) announced that CEO Warner Biddle will present at the Jefferies Global Healthcare Conference in London on Monday, November 17, 2025 at 1:00 p.m. GMT.
A live webcast will be available via the Investors section of Kyverna's website at ir.kyvernatx.com, and a replay will be posted for approximately 90 days after the conference.
Kyverna Therapeutics (NASDAQ: KYTX) closed a debt facility with Oxford Finance for up to $150 million, drawing an initial $25 million on November 3, 2025. The facility includes an initial tranche structure (totaling up to $150M across four tranches) and matures on October 1, 2030. Kyverna said the financing strengthens liquidity and supports late-stage programs in stiff person syndrome (SPS) and generalized myasthenia gravis (gMG) while accelerating pre-launch work.
Guidance updated: topline registrational SPS data now expected in early 2026 (narrowed from 1H 2026); BLA filing for SPS targeted in 1H 2026; MG Phase 3 enrollment to begin by end of 2025. Additional program readouts and an IND filing for KYV-102 are planned in 2025–2026.
Kyverna Therapeutics (NASDAQ: KYTX) announced positive interim Phase 2 data from the KYSA-6 study of KYV-101 in generalized myasthenia gravis on October 29, 2025.
In six treated patients (data cutoff Oct 3, 2025) a single 1×10^8 CAR+T dose produced mean MG-ADL -8.0 and QMG -7.7 point changes at 24 weeks; 100% (6/6) met co-primary clinical response thresholds and 100% were free of several background immunosuppressive treatments through 24 weeks. Safety showed no Grade ≥3 CRS and no ICANS; one Grade 4 neutropenia resolved to Grade 1 by cutoff.
FAQ
What is the current stock price of Kyverna Therapeutics (KYTX)?
What is the market cap of Kyverna Therapeutics (KYTX)?
